Stockscreener 앱 받기
4.07
1.21%
-0.05
시간 외 거래:
4.06
-0.01
-0.25%
전일 마감가:
$4.12
열려 있는:
$4.15
하루 거래량:
165.81K
Relative Volume:
0.56
시가총액:
$8.42M
수익:
-
순이익/손실:
$-29.77M
주가수익비율:
-0.2661
EPS:
-15.2954
순현금흐름:
$-24.23M
1주 성능:
+22.96%
1개월 성능:
-43.78%
6개월 성능:
-58.13%
1년 성능:
-90.91%
1일 변동 폭
$4.02
$4.2563
1주일 범위
$3.25
$4.3172
52주 변동 폭
$3.13
$91.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
MBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
4.07 | 8.53M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-09 | 재개 | H.C. Wainwright | Buy |
| 2025-02-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Moleculin Biotech regains Nasdaq listing compliance - MarketScreener
Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements - TipRanks
Moleculin Biotech Regains Nasdaq Compliance - TradingView — Track All Markets
Why Moleculin Biotech Inc. stock remains a top recommendation2026 world cup usa national team round of 32 midfield engines counter attacking tactical prediction breakdown - ulpravda.ru
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech’s Wild Ride: Is Tiny-Cap MBRX the Next Viral Moonshot or Total Trap? - AD HOC NEWS
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Biotech enters inducement offer agreements - MSN
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moleculin Biotech begins dosing subjects in combination therapy trial for AML - MSN
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million - Investing.com Nigeria
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million By Investing.com - Investing.com South Africa
Moleculin Biotech Amends Warrants to Boost Nasdaq Compliance - TipRanks
Moleculin Biotech Signs Warrant Amendment Agreements With Holders of Series E, F and G Warrants - TradingView — Track All Markets
Moleculin Biotech shares slide after release of pediatric brain tumor trial data - MSN
Why retail investors favor Moleculin Biotech Inc. stockJuly 2025 Movers & Weekly Momentum Stock Picks - Улправда
Will Moleculin Biotech Inc. stock rally after Fed decisions2025 Volatility Report & Long Hold Capital Preservation Tips - Улправда
Will Moleculin Biotech Inc. stock split attract more investorsMarket Performance Report & Safe Capital Growth Plans - Улправда
Moleculin Biotech Earnings Notes - Trefis
Moleculin Biotech (LTS:0K2H) EV-to-OCF : -0.07 (As of Dec. 19, 2025) - GuruFocus
How risky is Moleculin Biotech Inc. (MOL) stock compared to peersJuly 2025 Spike Watch & Target Return Focused Picks - DonanımHaber
Why Moleculin Biotech Inc. (MOL) stock is listed among top recommendationsJuly 2025 PreEarnings & Technical Pattern Based Signals - DonanımHaber
Earnings Report: Why Moleculin Biotech Inc. stock is considered a top pickJuly 2025 Snapshot & Weekly Setup with High ROI Potential - Улправда
Market Review: Why Moleculin Biotech Inc. stock could rally in 2025July 2025 Snapshot & Fast Gain Swing Alerts - DonanımHaber
What technical charts say about Moleculin Biotech Inc. stockMarket Risk Analysis & Smart Swing Trading Alerts - DonanımHaber
Why Moleculin Biotech Inc. stock could rally in 2025Global Markets & Verified Momentum Stock Watchlist - DonanımHaber
Aug Wrap: Why Moleculin Biotech Inc. stock is considered a top pickJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - Улправда
Why Moleculin Biotech Inc. stock is popular among millennialsWeekly Market Outlook & High Accuracy Swing Trade Signals - Улправда
Why hedge funds are buying Moleculin Biotech Inc. stockTrade Risk Summary & Accurate Trade Setup Notifications - ulpravda.ru
Moleculin Biotech reports positive phase 1 trial results - MSN
Moleculin Biotech stock falls after pediatric brain tumor trial results By Investing.com - Investing.com Australia
Moleculin Biotech’s Bold Move: Stock Split Announced - StocksToTrade
Moleculin’s brain cancer drug shows promise in pediatric trial By Investing.com - Investing.com Nigeria
Moleculin Shares Drop 17% Despite Positive Phase 1 WP1066 Data In Pediatric Brain Tumors - Nasdaq
Moleculin Biotech Prepares for 1-for-25 Reverse Split Amidst Clinical Advancements - timothysykes.com
Moleculin Biotech regains Nasdaq compliance - MSN
Moleculin's WP1066 Shows Immune Activity, Favorable Safety In Pediatric Brain Cancer Trial - Nasdaq
Moleculin announces positive phase 1 data for WP1066 in pediatric brain tumors - marketscreener.com
Moleculin Biotech’s Reverse Split Shocks Market - timothysykes.com
Moleculin’s brain cancer drug shows promise in pediatric trial - Investing.com
Moleculin Biotech stock falls after pediatric brain tumor trial results - Investing.com
Moleculin Biotech Reports Positive Phase 1 Trial Results - TipRanks
Moleculin Biotech Reports Positive Phase 1 Trial Results for WP1066 in Pediatric Brain Cancer Treatments - Quiver Quantitative
Moleculin Biotech, Inc. Announces Positive Phase 1 Trial Results for WP1066 - TradingView — Track All Markets
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):